The Difficult-to-Treat del 17 p Patient-A Case Report in Chronic Lymphocytic Leukemia.

Ana-Maria Moldovianu, Ana Manuela Crisan, Zsofia Varady, Daniel Coriu

Open access · goldAbstract readCase Reports

In one paragraph

Article in Medicina (Kaunas, Lithuania), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.1field-weighted citation impact, top 47% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ana-Maria MoldovianuDepartment of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 258 Fundeni Street, 022328 Bucharest, Romania.

Ana Manuela CrisanDepartment of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 258 Fundeni Street, 022328 Bucharest, Romania.

Zsofia VaradyDepartment of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 258 Fundeni Street, 022328 Bucharest, Romania.

Daniel CoriuDepartment of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 258 Fundeni Street, 022328 Bucharest, Romania.ORCID 0000-0002-7251-6079

Carol Davila University of Medicine and Pharmacy · ROInstitutul Clinic Fundeni · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) treatment strategies have evolved to include mechanism-driven drugs but now raise new questions regarding their optimum timing and sequencing. In high-risk patients, switching from pathway inhibitors to allogeneic stem cell transplantation (allo-HCT) is still a matter of intense debate. We report the case of a CLL patient with 17 p deletion treated with ibrutinib as a bridge to allo-HCT. Early relapse after allo-HCT urged the initiation of salvage therapy, including donor lymphocytes infusions, ibrutinib, and venetoclax. We aim to outline and discuss the potential benefits of novel therapies, the current role of allo-HCT in CLL, drug timing and sequencing, and the unmet need to improve the long-term outcome of high-risk CLL patients.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Lymphocytic, Chronic, B-CellHumansRecurrenceSalvage Therapy17 p deletionallogeneic stem cell transplantationchronic lymphocytic leukemia

Identifiers

PMID35056341

DOI10.3390/medicina58010033

PMCPMC8778873

OpenAlexW4200352660

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.